🚨BIG news 🚨 The ICR has received the Queen Elizabeth Prize for Higher and Further Education for our groundbreaking radiotherapy research. This work has improved cancer care worldwide—through advanced techniques, landmark trials, and training the next generation of oncologists. #QEdPrizes

Sign up for our webinar with @bursturology.bsky.social on Thursday 23 October, 09.00 to hear experts discuss the use of systemic anti-cancer treatment in metastatic prostate cancer and submit questions in advance 👇 www.natcan.org.uk/events/webin... See you there! @alison-tree.bsky.social

Webinar: The Use of Systemic Anti-Cancer Treatment in Metastatic Prostate Cancer - National Cancer Audit Collaborating Centre

In collaboration with BURST, the NPCA would like to invite you to our webinar “The use of systemic anti-cancer treatment in metastatic prostate cancer”. The webinar will explore the use of anti-system...

natcan.org.uk

BURSTurology@bursturology.bsky.social · 10mo ago

🤔 Got a question about the use of systemic anti-cancer treatment in metastatic prostate cancer? The @npca-natcan.bsky.social is here to help! Submit your questions and our expert panel will answer them in our webinar on 23 Oct 9am 👉 forms.gle/hzbAQwez2yAt... 🔗 NPCAxBURST.eventbrite.com

📢 The NPCA State of the Nation Report 2025 is OUT! Find the report, supplementary documents & provider results here www.natcan.org.uk/reports/npca... @natcan-news.bsky.social @hqip.bsky.social @prostatecanceruk.bsky.social @alison-tree.bsky.social @nhsengland.bsky.social Please share!

New comment piece by me & colleagues in @bmj.com on the using health data for research in UK Processes are so complex and so slow now that less research is happening and we are wasting the enormous potential of the NHS to drive innovation www.bmj.com/content/390/...

Health research in England is grinding to a halt

Wes Streeting, the UK health and social care secretary, announced in 2024 that “the NHS is broken” against a background of ballooning waiting lists, delays in disease detection, and reduced staff prod...

bmj.com

@alison-tree.bsky.social @ccparker.bsky.social #prostatecancer #pcsm

Science News@scinews.bsky.social · last yr.

This review discusses the contemporary management of all stages of prostate cancer, enabling holistic individualization of treatment, and describes the promise of future research to further improve outcomes. Open Access acsjournals.onlinelibrary.wiley.com/doi/10.3322/...

Excited to see the MARS trial highlighted here @cihangani.bsky.social @elekta.com @mrlconsortium.bsky.social @momentumstudy.bsky.social

Pleasure to be at the MRI in RT symposium at USZ @mguckenberger.bsky.social Meme of the day goes to Luca Boldrini

We had the SABR bone and nodes workshop today. @uksabr.bsky.social in collaboration with the RCR. Lots of discussion & learning for all within the SABR MDT. Collaboration at its best. Thank you to all those that attended and especially the speakers. @alison-tree.bsky.social @pattydiezh.bsky.social

Happy to share our review on hypo- and ultra-hypofractionation for prostate cancer radiotherapy, just published in Seminars in Radiation Oncology @alison-tree.bsky.social @harshanigreen.bsky.social Full-text link: authors.elsevier.com/a/1lFrI3lXQo...

Fantastic opening plenary at #UKOF25 by @charlesswanton.bsky.social Cancer initiation is not a simple matter of DNA damage from carcinogens. Forget everything you learned before!

💥 Our Transformational Impact Awards are now OPEN! 💥 This call supports our larger-scale research investments covering high-quality discovery science through to translational and clinical research. Submission deadline: 1pm, 23 September 2025 Apply now 👉 buff.ly/eCSnnCM

We are looking for two exceptional consultant uro-oncologists to come and join our team in Sutton. Please see further details 👇 www.royalmarsden.nhs.uk/current-vaca...

A great opportunity to work in cutting edge #clinicaltrials within a fun multidisciplinary team @notchonctrainees.bsky.social

RTTQA@rttqa.bsky.social · last yr.

Want to be part of shaping the future direction of RT research in the UK? An exciting opportunity has arisen to work as a research fellow within the @nihr.bsky.social RTTQA Group, based at Mount Vernon Cancer Centre. For more info please DM us! #radonc #rtqa www.nhsjobs.com/job/UK/Hertf...

Great news! If you have an idea for a new radiotherapy trial, please find the email below

@roberthuddart.bsky.social · last yr.

News for UK radiotherapy community. Pleased to say that thanks to @macmillancancer we have been able to establish #ctrad. We plan a proposals guidance meeting on 8.7.25 If you have a new trial idea and wish to attend please contact ctrad@macmillan.org to register

Excited to see the HERMES trial results in print www.sciencedirect.com/science/arti... Small trial but toxicity of 2 fractions looks promising at 24/27 Gy, no GI tox of G2 or higher out to 12 weeks @momentumstudy.bsky.social @icr.ac.uk

HERMES: Randomised trial of 2-fraction or 5-fraction MRI-guided adaptive prostate radiotherapy

To demonstrate safety and feasibility of 2-fraction stereotactic body radiotherapy (SBRT) for prostate cancer.This single centre, non-comparative, pha…

sciencedirect.com

What could be better than 5 days in Verona in October, learning about prostate cancer? Comprehensive multidisciplinary programme aimed at oncologists, urologists, radiologists and anyone else involved in treated prostate cancer. Spread the word!

Encouraging data on safety of 5-fraction SBRT for post-prostatectomy recurrence 👇

The Advanced Prostate Cancer Consensus Conference@apccc.bsky.social · last yr.

Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy jamanetwork.com/journals/jam... findings suggest that post-RP SBRT is a well-tolerated alternative to Conventionally Fractionated RT #ProstateCancer @silkegillessen.bsky.social 🚨

Don’t forget to register for the annual UK Oncology forum, which is FREE to attend. Breakout sessions covering topics including prostate cancer and radiotherapy, including Dr Ben O’Leary @icr.ac.uk, Dr Rovel Colaco, Dr Katie Spencer and Prof Stefanie Corradini oncology-forum.co.uk/register/

Congratulations to Professor Faivre-Finn on the ESTRO Breur award, and using your platform to encourage us all to address gender inequality in academic radiation oncology 👏 #ESTRO25

Congratulations to @montefiored.bsky.social for a great presentation of the ARISTOTLE trial 👏. Always learn a lot from an RCT, sometimes not the things you were expecting to learn #ESTRO2025

Significant benefit to focal boost in prostate cancer out to 10 years in FLAME trial #ESTRO2025 Fifteen percent of men avoid further treatment just due to the boost 🏆

Congratulations @montefiored.bsky.social & team 👏🏽 I remember talking to you in clinic about this as a registrar. Great to see the results and the impact for patients #ESTRO25 @thelancetoncol.bsky.social

Great summary from Piet Ost, summarising what we know about systemic therapy +/- SBRT (and vice versa) in prostate oligomets #ESTRO25

HYPO-RT-PC 10 year data presented at #ESTRO2025. Seven fractions def non-inferior to 39 fractions, suggestion that 7 fractions might even be more likely to cure?

Exciting data presented in ESTRO 2025 plenary: 5 fraction adjuvant breast RT (26 Gy) at least as good (and possibly better?) than 15 fractions @icr.ac.uk #ESTRO2025

⚠️ Another key finding of this study is that higher rates of metastatic prostate cancer were seen in regions with lower rates of prostate cancer diagnosis overall which may be linked to variation in the use of PSA testing.

#Radonc representation on @NCCN Treatment Guideline Committees is <10%, even for committees that recommend #radiation. Additionally, certain institutions have nominated relatively few ☢️👩‍⚕️ for their designated slots. Glad to see this 📰 finally published. www.advancesradonc.org/article/S245...

Representation of Radiation Oncologists on National Comprehensive Cancer Network Guideline Committees

The National Comprehensive Cancer Network (NCCN) guideline committees play a vital role in defining the standard of care for cancer management. Equitable specialty representation is crucial for unbias...

advancesradonc.org

Impt paper from @npca-natcan.bsky.social-geographic variation in prostate cancer diagnosis bmjoncology.bmj.com/content/4/1/... Areas with the HIGHEST risk of metastatic disease have the LOWEST incidence of all prostate cancer. Prostate cancer is curable if caught early @prostatecanceruk.bsky.social

Geographic, socioeconomic and demographic inequalities in the incidence of metastatic prostate cancer at time of diagnosis in England: a population-based evaluation

Objective To evaluate the area-based incidence of metastatic prostate cancer at diagnosis, reflecting the risk of late-stage diagnosis, and overall prostate cancer incidence, reflecting the risk of ov...

bmjoncology.bmj.com

The absolute callousness of announcing a 44% trade tariff against Myanmar this week, of all weeks.

🚨out today🚨 🎙️ Part 2 of our conversation with the excellent @achoud72.bsky.social on bladder preservation in bladder cancer🙌🏽 Once again making the case for bladder radiotherapy 🥁 Enjoy @rcradiologists.bsky.social www.buzzsprout.com/2342317/epis...

Episode 42: In the Clinic - Part 2 of Bladder preservation bladder cancer with Ananya Choudhury - Simply Oncology

Join us for our second part of our discussions with the excellent Professor Ananya Choudhury where we discuss the option of bladder preserving treatment in muscle invasive bladder cancer.In this episo...

buzzsprout.com